The NJ Pediatric AIDS Consortium (NJ-PAC) is recompeting for RFA AI-96- 001 to maintain its NIAID pediatric and perinatal-sponsored Clinical Trials Program. This program, funded since 1987, consists of an administrative unit, primary perinatal component, and Center for Laboratory Investigations (CLI) in the DAIID, Department of Pediatrics at the NJMS and 4 subunit clinical trial sites (Children Hospital of New Jersey, University Hospital, St. Joseph's Hospital and Medical Center, and Cooper Hospital/University Medical Center). Under this application, Newark Beth Israel Medical Center is proposed as a new subunit for conducting pediatric and perinatal clinical trials. Funding from NIAID will be by subcontract, covering research personnel at UMD/NJMS, Children's Hospital of NJ and St. Joseph's Hospital Medical Center, while Cooper Hospital/university Medical Center and the proposed NBI will be supported on a per-patient cost reimbursement basis for the first year of funding. Each site will have the opportunity to enroll HIV infected patients from their catchment area into this national network of clinical trials. Children's Hospital of NJ and Cooper Medical Center will enroll only infants, children and youths while University Hospital, St. Joseph and Newark Beth Israel will participate in enrollment of pediatric patients and pregnant women into perinatal clinical trials. The principal investigator, Dr. James Oleske, is overall responsible for the operation of this funded application. Dr. George McSherry is the medical director director and principal pediatric co-investigator, Dr. Arlene Bardeguez is the principal periantal co-investigator, Dr. Deborah Storm is study coordinator; each clinical subunit has a pediatric and/or perinatal investigator, study nurse, and pharmacy support. The overall goal is to enroll a total of 60 new HIV infected patients into national clinical trials which will include pregnant women, their infants, children and youth.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01AI025883-13S1
Application #
6415831
Study Section
Special Emphasis Panel (ZAI1 (01))
Program Officer
Batzold, Frederick
Project Start
1987-09-30
Project End
2002-02-28
Budget Start
2000-03-01
Budget End
2002-02-28
Support Year
13
Fiscal Year
2001
Total Cost
$1,491,974
Indirect Cost
Name
University of Medicine & Dentistry of NJ
Department
Pediatrics
Type
Schools of Medicine
DUNS #
605799469
City
Newark
State
NJ
Country
United States
Zip Code
07107
Cohn, Susan E; Umbleja, Triin; Mrus, Joseph et al. (2008) Prior illicit drug use and missed prenatal vitamins predict nonadherence to antiretroviral therapy in pregnancy: adherence analysis A5084. AIDS Patient Care STDS 22:29-40
McComsey, Grace A; Kang, Minhee; Ross, Allison C et al. (2008) Increased mtDNA levels without change in mitochondrial enzymes in peripheral blood mononuclear cells of infants born to HIV-infected mothers on antiretroviral therapy. HIV Clin Trials 9:126-36
Hitti, Jane; Andersen, Janet; McComsey, Grace et al. (2007) Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084. Am J Obstet Gynecol 196:331.e1-7
Livingston, Elizabeth G; Cohn, Susan E; Yang, Yang et al. (2007) Lipids and lactate in human immunodeficiency virus-1 infected pregnancies with or without protease inhibitor-based therapy. Obstet Gynecol 110:391-7
Palumbo, Paul; Wu, Hulin; Chadwick, Ellen et al. (2007) Virologic response to potent antiretroviral therapy and modeling of HIV dynamics in early pediatric infection. J Infect Dis 196:23-9
Al-Khan, Anthony; Colon, Jose; Palta, Vidya et al. (2003) Assisted reproductive technology for men and women infected with human immunodeficiency virus type 1. Clin Infect Dis 36:195-200
Eshleman, S H; Krogstad, P; Jackson, J B et al. (2001) Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377). J Infect Dis 183:1732-8
Buchacz, K; Cervia, J S; Lindsey, J C et al. (2001) Impact of protease inhibitor-containing combination antiretroviral therapies on height and weight growth in HIV-infected children. Pediatrics 108:E72
McSherry, G D; Shapiro, D E; Coombs, R W et al. (1999) The effects of zidovudine in the subset of infants infected with human immunodeficiency virus type-1 (Pediatric AIDS Clinical Trials Group Protocol 076). J Pediatr 134:717-24
McSherry, G D (1996) Human immunodeficiency-virus-related pulmonary infections in children. Semin Respir Infect 11:173-83

Showing the most recent 10 out of 17 publications